A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

被引：547

作者：

Mian-McCarthy, Sara ^{[19
]}

Agnandji, Selidji Todagbe ^{[1
,2
]}

Lell, Bertrand ^{[1
,2
]}

Fernandes, Jose Francisco ^{[1
,2
]}

Abossolo, Beatrice Peggy ^{[1
,2
]}

Methogo, Barbara Gaelle Nfono Ondo ^{[1
,2
]}

Kabwende, Anita Lumeka ^{[1
,2
]}

Adegnika, Ayola Akim ^{[1
,2
]}

Mordmueller, Benjamin ^{[1
,2
]}

Issifou, Saadou ^{[1
,2
]}

Kremsner, Peter Gottfried ^{[1
,2
]}

Sacarlal, Jahit ^{[3
,4
]}

Aide, Pedro ^{[3
,4
]}

Lanaspa, Miguel ^{[3
,4
]}

Aponte, John J. ^{[3
,4
]}

Machevo, Sonia ^{[3
,4
]}

Acacio, Sozinho ^{[3
,4
]}

Bulo, Helder ^{[3
,4
]}

Sigauque, Betuel ^{[3
,4
]}

Macete, Eusebio ^{[3
,4
]}

Alonso, Pedro ^{[3
,4
]}

Abdulla, Salim ^{[5
,6
]}

Salim, Nahya ^{[5
,6
]}

Minja, Rose ^{[5
,6
]}

Mpina, Maxmillian ^{[5
,6
]}

Ahmed, Saumu ^{[5
,6
]}

Ali, Ali Mohammed ^{[5
,6
]}

Mtoro, Ali Takadir ^{[5
,6
]}

Hamad, Ali Said ^{[5
,6
]}

Mutani, Paul ^{[5
,6
]}

Tanner, Marcel ^{[5
,6
]}

Tinto, Halidou ^{[7
,8
]}

D'Alessandro, Umberto ^{[7
,8
]}

Sorgho, Hermann ^{[7
,8
]}

Valea, Innocent ^{[7
,8
]}

Bihoun, Biebo ^{[7
,8
]}

Guiraud, Issa ^{[7
,8
]}

Kabore, Berenger ^{[7
,8
]}

Sombie, Olivier ^{[7
,8
]}

Guiguemde, Robert Tinga ^{[7
,8
]}

Ouedraogo, Jean Bosco ^{[7
,8
]}

Hamel, Mary J. ^{[9
]}

Kariuki, Simon ^{[9
]}

Oneko, Martina ^{[9
]}

Odero, Chris ^{[9
]}

Otieno, Kephas ^{[9
]}

Awino, Norbert ^{[9
]}

McMorrow, Meredith ^{[9
]}

Muturi-Kioi, Vincent ^{[9
]}

Laserson, Kayla F. ^{[9
]}

机构：

[1] Albert Schweitzer Hosp, Lambarene, Gabon

[2] Univ Tubingen, Inst Trop Med, Tubingen, Germany

[3] Ctr Invest Saude Manhica, Manhica, Mozambique

[4] Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Hosp Clin, Barcelona, Spain

[5] Ifakara Hlth Inst, Bagamoyo, Tanzania

[6] Swiss Trop & Publ Hlth Inst, Basel, Switzerland

[7] Inst Rech Sci Sante, Nanoro, Burkina Faso

[8] Inst Trop Med, B-2000 Antwerp, Belgium

[9] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya

[10] KEMRI Walter Reed Project, Kombewa, Kenya

[11] KEMRI Wellcome Trust Res Program, Kilifi, Kenya

[12] Kintampo Hlth Res Ctr, Kintampo, Ghana

[13] London Sch Hyg & Trop Med, London, England

[14] Natl Inst Med Res, Korogwe, Tanzania

[15] Univ Copenhagen, Copenhagen, Denmark

[16] Sch Med Sci, Kumasi, Ghana

[17] Univ N Carolina Project, Lilongwe, Malawi

[18] GlaxoSmithKline Vaccines, Wavre, Belgium

[19] PATH Malaria Vaccine Initiat, Commun & Advocacy Unit, Washington, DC 20001 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 367卷 / 24期

关键词：

III MULTICENTER TRIAL; CANDIDATE VACCINE; CASE-DEFINITION; FALCIPARUM-MALARIA; DATA-COLLECTION; DOUBLE-BLIND; SAFETY; IMMUNOGENICITY; EFFICACY; IMMUNIZATION;

D O I：

10.1056/NEJMoa1208394

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial. METHODS We administered RTS,S/AS01 or a comparator vaccine to 6537 infants who were 6 to 12 weeks of age at the time of the first vaccination in conjunction with Expanded Program on Immunization (EPI) vaccines in a three-dose monthly schedule. Vaccine efficacy against the first or only episode of clinical malaria during the 12 months after vaccination, a coprimary end point, was analyzed with the use of Cox regression. Vaccine efficacy against all malaria episodes, vaccine efficacy against severe malaria, safety, and immunogenicity were also assessed. RESULTS The incidence of the first or only episode of clinical malaria in the intention-to-treat population during the 14 months after the first dose of vaccine was 0.31 per person-year in the RTS,S/AS01 group and 0.40 per person-year in the control group, for a vaccine efficacy of 30.1% (95% confidence interval [ CI], 23.6 to 36.1). Vaccine efficacy in the per-protocol population was 31.3% (97.5% CI, 23.6 to 38.3). Vaccine efficacy against severe malaria was 26.0% (95% CI, -7.4 to 48.6) in the intention-to-treat population and 36.6% (95% CI, 4.6 to 57.7) in the per-protocol population. Serious adverse events occurred with a similar frequency in the two study groups. One month after administration of the third dose of RTS,S/AS01, 99.7% of children were positive for anti-circumsporozoite antibodies, with a geometric mean titer of 209 EU per milliliter (95% CI, 197 to 222). CONCLUSIONS The RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants. (Funded by GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative; RTS,S ClinicalTrials.gov number, NCT00866619.)

引用

页码：2284 / 2295

页数：12

共 33 条

[21] Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children [J].

Lievens, Marc ;

Aponte, John J. ;

Williamson, John ;

Mmbando, Bruno ;

Mohamed, Ali ;

Bejon, Philip ;

Leach, Amanda .

MALARIA JOURNAL, 2011, 10

[22] Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial [J].

Olotu, Ally ;

Lusingu, John ;

Leach, Amanda ;

Lievens, Marc ;

Vekemans, Johan ;

Msham, Salum ;

Lang, Trudie ;

Gould, Jayne ;

Dubois, Marie-Claude ;

Jongert, Erik ;

Vansadia, Preeti ;

Carter, Terrell ;

Njuguna, Patricia ;

Awuondo, Ken O. ;

Malabeja, Anangisye ;

Abdul, Omar ;

Gesase, Samwel ;

Mturi, Neema ;

Drakeley, Chris J. ;

Savarese, Barbara ;

Villafana, Tonya ;

Lapierre, Didier ;

Ballou, W. Ripley ;

Cohen, Joe ;

Lemnge, Martha M. ;

Peshu, Norbert ;

Marsh, Kevin ;

Riley, Eleanor M. ;

von Seidlein, Lorenz ;

Bejon, Philip .

LANCET INFECTIOUS DISEASES, 2011, 11 (02) :102-109

[23]

Prymula R, 2008, EXPERT OPIN BIOL TH, V8, P503, DOI [10.1517/14712598.8.4.503, 10.1517/14712598.8.4.503 ]

[24] Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants [J].

Siegrist, CA .

VACCINE, 2003, 21 (24) :3406-3412

[25] Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effects [J].

Steketee, Richard W. ;

Campbell, Carlos C. .

MALARIA JOURNAL, 2010, 9

[26] Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine [J].

Swysen, Christine ;

Vekemans, Johan ;

Bruls, Myriam ;

Oyakhirome, Sunny ;

Drakeley, Chris ;

Kremsner, Peter ;

Greenwood, Brian ;

Ofori-Anyinam, Opokua ;

Okech, Brenda ;

Villafana, Tonya ;

Carter, Terrell ;

Savarese, Barbara ;

Duse, Adriano ;

Reijman, Andrea ;

Ingram, Charlotte ;

Frean, John ;

Ogutu, Bernhards .

MALARIA JOURNAL, 2011, 10

[27]

Therneau TM, 2000, STAT BIOL HEALTH

[28] Pooled analysis of safety data from pediatric phase II RTS,S/AS malaria candidate vaccine trials [J].

Vekemans, Johan ;

Guerra, Yolanda ;

Lievens, Marc ;

Benns, Sarah ;

Lapierre, Didier ;

Leach, Amanda ;

Verstraeten, Thomas .

HUMAN VACCINES, 2011, 7 (12) :1309-1316

[29] Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care [J].

Vekemans, Johan ;

Marsh, Kevin ;

Greenwood, Brian ;

Leach, Amanda ;

Kabore, William ;

Soulanoudjingar, Solange ;

Asante, Kwaku Poku ;

Ansong, Daniel ;

Evans, Jennifer ;

Sacarlal, Jahit ;

Bejon, Philip ;

Kamthunzi, Portia ;

Salim, Nahya ;

Njuguna, Patricia ;

Hamel, Mary J. ;

Otieno, Walter ;

Gesase, Samwel ;

Schellenberg, David .

MALARIA JOURNAL, 2011, 10

[30] Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials [J].

White, Michael T. ;

Griffin, Jamie T. ;

Drakeley, Chris J. ;

Ghani, Azra C. .

MALARIA JOURNAL, 2010, 9 :82

← 1 2 3 4 →